Veloxis pays $46M DOJ settlement for kickbacks on transplant drug

Veloxis Pharmaceuticals settles criminal and civil DOJ allegations involving $46M in kickbacks to kidney transplant professionals to induce Envarsus prescriptions, with a three-year deferred prosecution agreement.